UBS Group’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $15.1M | Buy |
866,935
+275,753
| +47% | +$4.81M | ﹤0.01% | 2097 |
|
|
2025
Q1 | $7.44M | Sell |
591,182
-421,519
| -42% | -$5.3M | ﹤0.01% | 2632 |
|
|
2024
Q4 | $10.7M | Buy |
1,012,701
+902,819
| +822% | +$9.52M | ﹤0.01% | 2266 |
|
|
2024
Q3 | $1.59M | Buy |
109,882
+44,960
| +69% | +$652K | ﹤0.01% | 3217 |
|
|
2024
Q2 | $552K | Sell |
64,922
-39,519
| -38% | -$336K | ﹤0.01% | 3857 |
|
|
2024
Q1 | $1.07M | Buy |
104,441
+102,713
| +5,944% | +$1.05M | ﹤0.01% | 3503 |
|
|
2023
Q4 | $9.47K | Buy |
+1,728
| New | +$9.47K | ﹤0.01% | 6281 |
|
|
2023
Q2 | – | Sell |
-2,903
| Closed | -$18.9K | – | 8366 |
|
|
2023
Q1 | $18.9K | Buy |
+2,903
| New | +$18.9K | ﹤0.01% | 6033 |
|
|
2022
Q4 | – | Sell |
-12
| Closed | – | – | 9796 |
|
|
2022
Q3 | $0 | Sell |
12
-490
| -98% | – | ﹤0.01% | 9653 |
|
|
2022
Q2 | $2K | Sell |
502
-11
| -2% | -$44 | ﹤0.01% | 8568 |
|
|
2022
Q1 | $2K | Sell |
513
-78,327
| -99% | -$305K | ﹤0.01% | 8610 |
|
|
2021
Q4 | $525K | Buy |
78,840
+65,110
| +474% | +$434K | ﹤0.01% | 3941 |
|
|
2021
Q3 | $137K | Buy |
13,730
+13,555
| +7,746% | +$135K | ﹤0.01% | 4543 |
|
|
2021
Q2 | $5K | Sell |
175
-3,364
| -95% | -$96.1K | ﹤0.01% | 7460 |
|
|
2021
Q1 | $154K | Buy |
3,539
+3,446
| +3,705% | +$150K | ﹤0.01% | 4668 |
|
|
2020
Q4 | $4K | Buy |
+93
| New | +$4K | ﹤0.01% | 6899 |
|